Roflumilast
- Generic Name
- Roflumilast
- Brand Names
- Daliresp, Zoryve, Daxas
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14Cl2F2N2O3
- CAS Number
- 162401-32-3
- Unique Ingredient Identifier
- 0P6C6ZOP5U
- Background
Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium. The resultant increase in intracellular cAMP induced by ro...
- Indication
Oral roflumilast is indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Topical roflumilast is indicated to treat plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
- Associated Conditions
- Exacerbation of COPD, Psoriasis Vulgaris (Plaque Psoriasis)
- Associated Therapies
- -
Roflumilast and TMS Motor Plasticity
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 20
- Registration Number
- NCT06457191
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Rao Dermatology
- Target Recruit Count
- 3
- Registration Number
- NCT06440473
- Locations
- 🇺🇸
Rao Dermatology, Atlantic Highlands, New Jersey, United States
Efficacy of Roflumilast in Prevention of Peripheral Neuropathy
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 60
- Registration Number
- NCT05884281
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 414
- Registration Number
- NCT05763082
- Locations
- 🇺🇸
DS Research, Louisville, Kentucky, United States
Roflumilast Versus Methotrexate in Psoriasis
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 30
- Registration Number
- NCT05684744
- Locations
- 🇪🇬
Cairo University, Cairo, Egypt
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 45
- Registration Number
- NCT05418049
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT05369793
- Locations
- 🇪🇬
Asmaa Elshafey Elsharab, Tanta, Egypt
The Possible Effects of Roflumilast on Obesity Related Disorders
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 66
- Registration Number
- NCT04800172
- Locations
- 🇪🇬
Sara Mohammad Zayed, Tanta, Egypt
Possible Role of Roflumilast in Diabetic Nephropathy
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 48
- Registration Number
- NCT04755946
Roflumilast as add-on Therapy in Early Cases of ARDS
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 76
- Registration Number
- NCT04744090
- Locations
- 🇪🇬
Misr International Hospital, Giza, Doki, Egypt
🇪🇬Cairo University Hospitals, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.